ReviewThe British journal of radiology2026
Is there already value in "total body PET" imaging in neurology?
Review in The British journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
"Total Body" PET (TBP) represents a step change for all of PET, and brain imaging is no exception. Multiple benefits are already being seen. Lower injected doses benefit patients and staff and facilitate multitracer research. Shortened acquisition times for suitable radiopharmaceuticals enable better patient comfort and reduce the need for general anesthesia in children (albeit then partially negating the dose benefit). Later scanning enabled by the higher sensitivity palliates restrictions in tracer availability and allows better modeling. The large axial field-of-view enables better quantification via assessment of intravascular radioactivity concentrations. Early short-frame dynamic scanning has already enabled obtaining quantitative brain perfusion measurements for several radiopharmaceuticals. The large field-of-view allows assessment of brain-body interactions and multiorgan repercussions of disease. Despite some technical and methodological challenges remaining, TBP already offers added value in brain imaging, with exciting times ahead.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.